↓ Skip to main content

Neuropilin-1 as Therapeutic Target for Malignant Melanoma

Overview of attention for article published in Frontiers in oncology, June 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

twitter
6 X users
patent
5 patents

Citations

dimensions_citation
69 Dimensions

Readers on

mendeley
118 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Neuropilin-1 as Therapeutic Target for Malignant Melanoma
Published in
Frontiers in oncology, June 2015
DOI 10.3389/fonc.2015.00125
Pubmed ID
Authors

Grazia Graziani, Pedro M. Lacal

Abstract

Neuropilin-1 (NRP-1) is a transmembrane glycoprotein that acts as a co-receptor for various members of the vascular endothelial growth factor (VEGF) family. Its ability to bind or modulate the activity of a number of other extracellular ligands, such as class 3 semaphorins, TGF-β, HGF, FGF, and PDGF, has suggested the involvement of NRP-1 in a variety of physiological and pathological processes. Actually, this co-receptor has been implicated in axon guidance, angiogenesis, and immune responses. NRP-1 is also expressed in a variety of cancers (prostate, lung, pancreatic, or colon carcinoma, melanoma, astrocytoma, glioblastoma, and neuroblastoma), suggesting a critical role in tumor progression. Moreover, a growing amount of evidence indicates that NRP-1 might display important functions independently of other VEGF receptors. In particular, in the absence of VEGFR-1/2, NRP-1 promotes melanoma invasiveness, through the activation of selected integrins, by stimulating VEGF-A and metalloproteinases secretion and modulating specific signal transduction pathways. This review is focused on the role of NRP-1 in melanoma aggressiveness and on the evidence supporting its use as target of therapies for metastatic melanoma.

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 118 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 <1%
United States 1 <1%
Italy 1 <1%
Unknown 115 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 27 23%
Researcher 22 19%
Student > Bachelor 12 10%
Student > Master 9 8%
Student > Postgraduate 8 7%
Other 12 10%
Unknown 28 24%
Readers by discipline Count As %
Agricultural and Biological Sciences 24 20%
Medicine and Dentistry 17 14%
Biochemistry, Genetics and Molecular Biology 16 14%
Immunology and Microbiology 16 14%
Pharmacology, Toxicology and Pharmaceutical Science 7 6%
Other 9 8%
Unknown 29 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 October 2021.
All research outputs
#2,755,225
of 26,388,722 outputs
Outputs from Frontiers in oncology
#684
of 23,036 outputs
Outputs of similar age
#33,285
of 282,239 outputs
Outputs of similar age from Frontiers in oncology
#4
of 71 outputs
Altmetric has tracked 26,388,722 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 23,036 research outputs from this source. They receive a mean Attention Score of 3.2. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 282,239 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.